Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy

Figure 5

Loss of RASSF2 enhances Ras-mediated signaling pathways. Lysates from the control H441 cells and those stably transfected with the RASSF2 shRNA constructs were prepared, fractionated on SDS gels, and immunoblotted with antibodies against phosphorylated or total AKT. Loss of RASSF2 expression increased the levels of phosphorylated AKT.